Autopsy report · NCT03256721

Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC

“Due to the enrollment was slow and exceeded the expected enrollment time”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years before it stopped.
• 37 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Fuzhou General Hospital

Sponsor type

University, hospital or other

Conditions

Nonsmall Cell Lung Cancer

Interventions

Apatinib/docetaxel/pemetrexed; docetaxel/pemetrexed

Participants

37

Sites

1

Countries

China

Trials that died the same way

• A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting
  “Enrollment was too slow” (86% match in meaning)
• The Impact of Nebivolol Versus Metoprolol on Quality of Life
  “due to slow enrollment” (82% match in meaning)
• Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib
  “Slower than expected enrollment” (81% match in meaning)
• EXCimEr Laser for Long lENgTh Lesions in Below-The-Knee Arteries Study
  “too slow enrollment” (80% match in meaning)
• Zileuton CR vs Placebo in Poorly Controlled Asthma Patients on Moderate Dose ICS
  “Slower than anticipated enrollment” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.